Kenneth Moch

Mr. Moch has more than 30 years of experience in building and leading pioneering private and public life science companies, most recently as the president and CEO of Cognition Therapeutics. He previously has served as the president and CEO of Chimerix, Biomedical Enterprises, Alteon and Biocyte Corporation, where he pioneered the use of cord blood stem cells in transplantation therapy and launched the world’s first cord blood stem cell bank. He started his career in biotechnology as a co-founder of The Liposome Company. Prior to Cognition, Mr. Moch was a managing partner of The Salutramed Group, where he provided strategic and tactical counsel to biotechnology and medical products companies. Mr. Moch currently serves on the board of Zynerba Pharmaceuticals and is a founding member of the New York University Working Group of Compassionate Use and Pre-Approval Access. He served for over a decade on the Governing Board of the Biotechnology Innovation Association (BIO) and is a past Chairman of BioNJ.

Mr. Moch holds a bachelor’s degree in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.